ISOT Consensus Statement for the Kidney Transplant Recipient and Living Donor with a Previous Diagnosis of COVID-19

Introduction

National Organ The and Tissue Transplant Organization (NOTTO) has previously published transplant-specific guidelines with reference to coronavirus disease 2019 (COVID-19).[1] In India, the mortality rate is higher in dialysis patients with COVID-19 (12%-30%) posttransplant than in COVID-19 patients (11.3%),both are higher than in the general population (<2%).[2-5] With the resumption of kidney transplant program in various parts of India, new issues are expected to arise. There is uncertainty regarding the safety of performing kidney, [6-8] liver, [9-12] or lung^[13] transplantation in a recipient recently recovered from COVID-19. At present, we have limited evidence-based information about the safety feasibility of kidney transplantation from living donors who have recovered from COVID-19.[14] Recently, Indian multicenter cohort studies have reported successful kidney transplantations in recipients from living donors with a previous diagnosis of COVID-19.[15,16]

Guidelines of Other Professional Societies

The American Society of Transplantation (AST) recommends that the patient who recovered after COVID-19 should be asymptomatic and should preferably have two negative SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) polymerase chain reaction (PCR) tests done at least 24 hours apart in view of the limited sensitivity (70%) of a single test, although the optimal timing of multiple tests is unknown.^[17-20] The American Society of Anesthesiologists and Anesthesia Patient Safety Foundation Joint Statement

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

 $\textbf{For reprints contact:} \ WKHLRPMedknow_reprints@wolterskluwer.com$

on elective surgery and anesthesia for patients after COVID-19 infection suggests a waiting time from the date of COVID-19 diagnosis to surgery as follows:

- a. four weeks for an asymptomatic patient or one who has recovered from only mild, nonrespiratory symptoms;
- b. six weeks for a symptomatic patient (e.g., cough, dyspnea) who did not require hospitalization;
- eight to 10 weeks for a symptomatic patient with comorbidities such as diabetes, immunocompromized state, or hospitalization; and
- d. twelve weeks for a patient who was admitted to an intensive care unit due to COVID-19 infection.^[20]

The United Network for Organ Sharing/ American Society of Transplantation suggests proceeding for transplant from a previously infected potential donor if

- a. the timing is between 21 and 90 days from initial symptoms,
- b. the symptoms have resolved, and
- c. an infectious disease expert is consulted.[21]

National Institute for Clinical Excellence guidelines for live donors COVID-19 recovered infection recommend deferring transplants 28 days and 14 days of comprehensive social distancing and hand hygiene measures. Donation should resume only after the donor is clinically asymptomatic and has negative nasopharyngeal swab test result for nCoV (novel coronavirus) 2019 and another negative test within 3 days before donation.[22] The NOTTO guidelines suggest accepting a donor with a previous diagnosis of COVID-19 with documented two negative COVID-19 tests and complete symptom resolution for 28 days and another negative test at the time of donation.[1]

How to cite this article: Kute VB, Guleria S, Bhalla AK, Sharma A, Agarwal SK, Sahay M, *et al.* ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19. Indian J Nephrology 2022;32:288-90.

Vivek B. Kute. Sandeep Guleria¹, Anil K Bhalla², Ashish Sharma³. SK Agarwal⁵, Manisha Sahay⁶, Santosh Varughese⁷, Narayan Prasad8, PP Varma⁹, Sunil Shroff¹⁰, Harsh Vardhan¹¹, Manish Balwani¹², Shruti Dave¹³, Dhamendra Bhadauria⁸. Manish Rathi⁴, Dhananjay Agarwal¹⁴, Pankaj Shah¹⁵, Jai Prakash¹⁶

Department of Nephrology, Institute of Kidney Diseases and Research Center, Dr HL Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, ¹Department of Transplantation Surgery, Indraprastha Apollo Hospital, New Delhi, ²Department of Nephrology, Sir Ganga Ram Hospital, New Delhi, ³Departments of Transplantation Surgery and ⁴Nephrology, Postgraduate

Received: 13-03-2021 **Accepted:** 29-03-2021 **Published:** 11-05-2022



Institute of Medical Education and Research (PGIMER), Chandigarh, ⁵Department of Nephrology, All India Institute of Medical Sciences, New Delhi, ⁶Department of Nephrology, Osmania Medical College, Hyderabad, Telangana, ⁷Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, ⁸Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, Utter Pradesh, ⁹Department of Nephrology, Primus Super Speciality Hospital, Delhi, New Delhi, ¹⁰MOHAN Foundation, Chennai, ¹¹Department of Nephrology, Patna Medical College, Patna, Bihar, ¹²Department of Nephrology, Jawaharlal Nehru Medical College, Sawangi, Wardha, Maharashtra, ¹³Department of Pathology, IKDRC-ITS, Ahmedabad, Gujarat, ¹⁴Department of Nephrology, SMS Hospital, Jaipur, Rajasthan, ¹⁵Department of Nephrology Gujarat University of Transplantation Sciences, Ahmedabad, Gujarat, ¹⁶President, Indian Society of Organ Transplantation, Former Professor and Head Nephology Banaras Hindu University, Varanasi, Utter Pradesh, India

Address for correspondence:

Dr. Vivek Kute,

Professor, Nephrology and Transplantation, Institute of Kidney Diseases and Research Center and Dr. H L Trivedi Institute of Transplantation Sciences, Ahmedabad - 380 016, Gujarat, Secretary, Indian Society of Organ Transplantation, Lucknow - 226 014, Uttar Pradesh, India. E-mail: drvivekkute@rediffmail.com

Consensus Statement for Kidney Transplant Recipient and Donor with a Previous Diagnosis of COVID-19

We recommend that prospective kidney transplant recipients and donors with a previous diagnosis of COVID-19 should be considered for transplantation after comprehensive pretransplant evaluation using a combination of clinical, radiologic, and laboratory criteria, with individualized risk—benefit analysis.

Based on the currently available limited data, we suggest that the kidney transplant recipient and the prospective living donor with a previous diagnosis of COVID-19 should be considered for transplantation according to the following criteria:

- A. Regular social distancing, hand hygiene, and face mask use after recovery from COVID-19 infection
- B. Complete symptom resolution for at least 28 days. The ideal disease-free interval is unknown. The appropriate length of time between recovery from COVID-19 and surgery with respect to minimizing postoperative complications should be individualized, taking into consideration the symptoms, COVID-19 severity, associated comorbidities, and the benefit—risk ratio of further delaying the surgery.
- C. Documented *two negative SARS-CoV-2 PCR tests*, including one negative test at the time of transplant surgery. This is done to avoid known false-negative rates of single PCR test in COVID-19. The two negative PCR tests should be at least 24 hours apart because of the limited sensitivity (70%) of a single test.
- D. *Normal chest imaging* by computed tomography (CT) scan within 24 to 72 hours prior to transplants
- E. Donor-recipient pair should sign *written informed* consent explaining them the individualized risk-benefit analysis, including a potential risk of COVID-19 infection because of reactivation or reinfection during hospital stay and after transplant.
- F. Adequate screening in pretransplant evaluation with special attention given to the cardiopulmonary system by a multidisciplinary team and a planned regular long-term follow-up after discharge. Enhanced frequent follow-up should be ensured by telemedicine or face-to-face as required and feasible.

We suggest using standard drugs and doses of induction and maintenance immunosuppressive drugs based on the recipient's immune risk stratification as was being practiced before COVID-19.

We also recommend that the donor-recipient pair must be advised to continue to take safety precautions posttransplant and should get a prompt PCR testing and treatment if they have any suspicious symptoms of COVID-19 infection due to reactivation or reinfection after the transplantation.

We recommend that the transplant recipients and their household members should be vaccinated with ANY coronavirus vaccine that is authorized and approved for use by the local health authority. The World Health Organization suggests that individuals may wish to defer their own COVID-19 vaccination for up to 6 months from the time of SARS-CoV-2 infection.^[23] The Ministry of Health and Family Welfare, Government of India, suggests that the infected individuals should defer COVID-19 vaccination for 14 days after symptoms resolution. [24] According to the Centers for Disease Control and Prevention, there is no recommended minimum interval between recovery from the infection and vaccination. Current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after the initial infection but may increase with time due to decreasing neutralizing antibody titers. Vaccination should be deferred for at least 90 days^[25] in people who previously received passive antibody therapy such as convalescent plasma as part of COVID-19 treatment.

Disclaimer

COVID-19 pandemic is evolving in a dynamic manner. Therefore, this consensus statement is a live and dynamic document and will require updating as per the evolving situation.

Note: This special article is being published simultaneously in the *Indian Journal of Transplantation* and the *Indian Journal of Nephrology*.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Kute V, Guleria S, Prakash J, Shroff S, Prasad N, Agarwal SK, et al. NOTTO transplant specific guidelines with reference to COVID-19. Indian J Nephrol 2020;30:215-20.
- Deshpande R, Dash S, Bahadur MM, Thamba A, Pathan AK, Dave K, et al. Study of COVID-19 pandemic in representative dialysis population across Mumbai, India: An observational multicentric analysis. J Assoc Physicians India 2020;68:13-7.
- Trivedi M, Shingada A, Shah M, Khanna U, Karnik ND, Ramachandran R, et al. Impact of COVID-19 on maintenance haemodialysis patients: The Indian scenario. Nephrology (Carlton) 2020;26:e13760.
- Kute VB, Bhalla AK, Guleria S, Ray DS, Bahadur MM, Shingare A, et al. Clinical profile and outcome of COVID-19 in 250 kidney transplant recipients: A Multicenter cohort study from India. Transplantation 2020. Publish Ahead of Print. doi: 10.1097/TP.00000000000003593.
- 5. https://www.mohfw.gov.in/[Last accessed on 2021 Mar 1].
- Varotti G, Dodi F, Garibotto G, Fontana I. Successful kidney transplantation after COVID-19. Transpl Int 2020;33:1333-4.
- Singh N, Tandukar S, Zibari G, Naseer MS, Amiri HS, Samaniego-Picota MD. Successful simultaneous pancreas and kidney transplant in a patient post-COVID-19 infection. Kidney Int 2020;98:1615-6.
- Waghmare I, Shingare A, Bahadur M. ABO incompatible kidney transplant after recovery from severe COVID-19 pneumonia. Korean J Transplant 2020;34(Suppl 1):S56-6.
- Dhand A, Bodin R, Wolf DC, Schluger A, Nabors C, Nog R, et al. Successful liver transplantation in a patient recovered from COVID-19. Transpl Infect Dis 2020:e13492. doi: 10.1111/tid.13492.
- Martini S, Patrono D, Pittaluga F, Brunetto MR, Lupo F, Amoroso A, et al. Urgent liver transplantation soon after recovery from COVID-19 in a patient with decompensated liver cirrhosis. Hepatol Commun 2020;5:144-5.
- Raut V, Sonavane A, Shah K, Raj CA, Thorat A, Sawant A, et al. Successful liver transplantation immediately after recovery from COVID-19 in a highly endemic area. Transpl Int 2021;34:376-7.
- Niess H, Börner N, Muenchhoff M, Khatamzas E, Stangl M, Graf A, et al. Liver transplantation in a patient after COVID-19-Rapid loss of antibodies and prolonged viral RNA shedding. Am J Transplant 2020. doi: 10.1111/ajt.16349.
- Bharat A, Querrey M, Markov NS, Kim S, Kurihara C, Garza-Castillon R, et al. Lung transplantation for patients with severe COVID-19. Sci Transl Med 2020;12:eabe4282.

- Hong HL, Kim SH, Choi DL, Kwon HH. A case of coronavirus disease 2019-infected liver transplant donor. Am J Transplant 2020;20:2938-41.
- Kute VB, Ray DS, Yadav DK, Pathak V, Bhalla AK, Godara S, et al. A multi-centre cohort study from India of 75 kidney transplants in recipients recovered after COVID-19. Transplantation (accepted for publicationTPA-2021-0057R1). doi: 10.1097/TP.0000000000003740.
- 17. American Society of Transplantation. 2019-nCoV (Coronavirus): FAQs for Organ Transplantation. Availablefrom: https://www.myast.org/sites/default/files/COVID19%20FAQ%20Tx%20 Centers%2010.26.2020.pdf. [Last accessed on 2021 Jan 1].
- 18. Galvan NTN, Moreno NF, Garza JE, Bourgeois S, Hemmersbach-Miller M, Murthy B, *et al.* Donor and transplant candidate selection for solid organ transplantation during the COVID-19 pandemic. Am J Transplant 2020;20:3113-22.
- Ritschl PV, Nevermann N, Wiering L, Wu HH, Moroder P, Brandl A, et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy society recommendation consensus approach. Am J Transplant 2020;20:1826-36.
- 20. https://www.asahq.org/about-asa/newsroom/news-releases/2020/12/asa-and-apsf-joint-statement-on-electivesurg ery-and-anesthesia-for-patients-after-covid-19-infection. [Last accessed on 2021 Jan 1].
- Recommendations and Guidance for Organ Donor Testing, American Society of Transplantation. AST COVID-19 Information. Available from: https://www.myast.org/ covid-19-information [Last accessed on 2020 Nov 15].
- https://www.nice.org.uk/guidance/ng178/chapter/3-Transplant-donors [Last acessed on 2021 Mar 1].
- 23. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. Available from: https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know?gclid=CjwKCAiAp4KCBhB6EiwAxRxbpAZAQRkAr8iNenG8a5HEtwJhhFXsr25o-ds-A1kcKWQVbS3oxeDGexoClwIQAvD_BwE. [Last accessed on 2021 Mar 12].
- https://www.mohfw.gov.in/covid_vaccination/vaccination/index. html. [Last accessed on 2021 Mar 12].
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Available from: https://www.mohfw.gov.in/covid_vaccination/vaccination/index. html. [Last accessed on 2021 Mar 12].